AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05093673 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: 2 mA of cathodal tDCS is induced between two 5cm X 5cm saline soaked sponges where the cathode sponge is placed on the right cerebellum. Ramping up of the current to 2 mA occurs over 15-30 seconds to allow participants to habituate to the tingling sensation. Then, the current will be ramped back down to 0 mA in the sham condition. Termination of the stimulation after the ramping up process is generally undetectable, and the brief duration of stimulation yields no functional effects.
Study NCT05996562 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary Artery Denervation
Description: Contrast pulmonary artery (PA) angiography will be performed to localize the pulmonary artery bifurcation level and calculate the PA diameter. Once the anatomy deemed acceptable, the radiofrequency ablation catheter will be introduced into ostium of the left PA and the distal bifurcation area of the main PA.~The catheter will be manoeuvred within the PA to allow energy delivery in a circumferential manner to ensure that the electrodes are tightly in contact with the endovascular surface. About three ablations at 45-55°C for 120 seconds each will be performed in ostium of the left PA and the distal bifurcation area of the main PA.
Study NCT04917471 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beet root juice
Description: 70 ml bid
Study NCT04917471 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo juice
Description: 70 ml bid
Study NCT06421636 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT06502171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib Oral Tablet
Description: Cabozantinib will be taken once a day. It must be swallowed whole and not crushed and taken on an empty stomach. The dose will depend on when a participant enrolls on the study. First group will take 20 mg.~If participants are enrolled early in this study, they may receive doses that are lower than those who are enrolled later. Participants will be told what dose they will take when they start the study. Once a dose is started, the dose will not be increased. However, a dose can be reduced up to 2 times if a participant experience adverse events.~Cabozantinib may be taken simultaneously with selumetinib.
Study NCT06502171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib Oral Capsule
Description: Selumetinib will be taken twice a day, at least 6 hours apart. It must be swallowed whole and not crushed and taken on an empty stomach. The dose will depend on when a participant enrolls on the study. First group will take 15 mg twice a day.~If participants are enrolled early in this study, they may receive doses that are lower than those who are enrolled later. Participants will be told what dose they will take when they start the study. Once a dose is started, the dose will not be increased. However, a dose can be reduced up to 2 times if a participant experience adverse events.
Study NCT04938193 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 68Ga-citrate PET/CT
Description: PET/CT Imaging with 68Ga-citrate PET/CT injection
Study NCT05516758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peresolimab
Description: Administered subcutaneously (SC)
Study NCT05516758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study NCT05316753 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardioversion with a pulsed biphasic waveform
Description: Cardioversion with a pulsed biphasic waveform
Study NCT05316753 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cardioversion with a biphasic truncated exponential waveform
Description: Cardioversion with a biphasic truncated exponential waveform
Study NCT05464641 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxford knee score
Description: The Oxford Knee Score (OKS) is a 12-item patient-reported PRO, low score worse
Study NCT05743946 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trikafta
Description: Participants will be given elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg (two pills once daily in the morning) and ivacaftor 150 mg (once daily in the evening), as the FDA-registered agent, Trikafta. Dose and schedule will be identical to what has already been FDA-approved for effective treatment of cystic fibrosis.
Study NCT04771130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-11417
Description: Oral administration for 10, 21, 14 or 28 days on a 28-day cycle.
Study NCT04771130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Intravenous or subcutaneous administration for 7 days.
Study NCT04771130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole
Description: Oral administration for 8 days on second cycle only.
Study NCT05907954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darovasertib
Description: Oral, potent, selective inhibitor of Protein Kinase C
Study NCT06435364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimilation
Description: This non-invasive system is activated by the cutaneous distribution of vagus nerve afferents through the external ear. Somatosensory innervation is provided by the auricular branch.
Study NCT06435364 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy
Description: Manual therapy is mostly defined by the tissue targeted by the practitioner; it can be joint biased, muscle and connective tissue biased and/or neurovascular system biased techniques.
Study NCT05762250 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auricular Acupuncture
Description: Within the NADA protocol, 5 defined points on the patient's ears are treated according to a standardized concept (shen men, kidney, lung, liver, vegetative I).
Study NCT06324422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise intervention
Description: Participants in this arm are randomized to perform 12 weeks of supervised high intensity progressive aerobic exercise comprising continuous and/or interval cycling-, rowing- or cross-trainer sessions, increasing from 30 minutes towards 60 minutes with intensity increasing from 65 to 90% of individual maximum heart rate. The 12 weeks of aerobic exercise are followed by 12 weeks of habitual lifestyle (follow up period).
Study NCT06324422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance exercise intervention
Description: Participants in this arm are randomized to a 24-week waitlist control group. The control group will continue their habitual lifestyle throughout the 24 weeks. After 24 weeks, the waitlist control group will begin a 12 week supervised resistance exercise intervention comprising machine exercises in 3 to 5 sets with 2-3 minutes rest in between and a decrease from 12 to 6 repetitions in parallel with intensity increasing from 15RM (repetition maximum) to 8 RM.
Study NCT04771130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-11417
Description: Oral administration for 28 days on a 28-day cycle.
Study NCT06393517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06954522 IR (Formulation 1)
Description: Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 1 by mouth
Study NCT04771130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-11417
Description: Oral administration for 10, 14 or 21 days on a 28-day
Study NCT06443502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab intravenous infusion.
Study NCT06443502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concomitant Antibiotic Therapy
Description: Ciprofloxacin, metronidazole, vancomycin, amoxicillin clavulanate or rifaximin.
Study NCT05590455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab Injection
Description: one sub-cutaneous injection, every 2 weeks for 10 weeks (total 6 injections), started as soon as possible during the first 3 days of antituberculosis treatment and high-dose steroids
Study NCT06185413 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Participatory system dynamics approach
Description: First, local health profiles of children will be collected and used to engage key leaders and stakeholders from intervention communities and municipal administrations in participatory processes. These will be used to develop a systems map of drivers of PA behaviour in schoolchildren aged 6-12 years in the local communities. Second, based on the systems map, stakeholders from the civic and private sectors will be involved in developing and implementing actions to promote healthy PA behaviour through system changes.
Study NCT05227027 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Game Module
Description: Receive access to the the game module through the free, 'Smoke Free' smartphone application
Study NCT05227027 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoke Free smartphone application
Description: Receive educational intervention through the free 'Smoke Free' smartphone application (core version of the app)
Study NCT05227027 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoke Free smartphone application
Description: Receive educational intervention through the free 'Smoke Free' smartphone application (core version of the app)
Study NCT06048380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ripasudil
Description: Glanatec Ophthalmic Solution 0.4% W/V with ripasudil hydrochloride hydrate as active ingredient is currently being used by patients with ocular hypertension or open-angle glaucoma.~Inhibition of Rho kinase to facilitate aqueous outflow from the conventional outflow pathway via the trabecular meshwork and Schlemm's canal has been suggested as the IOP-lowering mechanism of action by ripasudil.
Study NCT06048380 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline eye drops
Study NCT05278780 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Screening for eligibility
Description: Asynchronous screening
Study NCT05925101 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extinction-only condition
Description: In this condition, therapists will place destructive behavior on extinction and deliver no reinforcement for functional communication responses (FCRs).
Study NCT04811989 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Instructive video on diabetic foot care
Description: In the video, the diabetic foot care is presented verbally and appropriately captioned, as well as exemplified by real patients and health professionals from the hospital
Study NCT05925101 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rate-drop condition
Description: In this condition,we will place destructive behavior on extinction and deliver the functional reinforcer contingent on the FCR on a VI 15-s schedule. This change from a VI 1.5-s schedule for destructive behavior in baseline to a VI 15-s schedule for the FCR during FCT will produce a large drop in reinforcement rate during FCT relative to baseline.
Study NCT04811989 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informative leaflet with real-time guided reading
Description: The leaflet has information about diabetic foot care. Researcher will guide its reading with patients.
Study NCT04811989 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Informative leaflet to read at home
Description: Patients receive a leaflet about diabetic foot care to read at home.
Study NCT04811989 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-to-face teaching
Description: Face-to-face teaching includes the teaching about diabetic foot care during the consultation by health professionals.
Study NCT04811989 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face teaching
Description: Face-to-face teaching includes the teaching about diabetic foot care during the consultation by health professionals.
Study NCT05925101 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rate-hold condition
Description: In this condition, we will place destructive behavior on extinction and deliver the functional reinforcer contingent on the FCR on a yoked VI 1.5-s schedule that exactly matches the rate and timing of reinforcer deliveries for destructive behavior in baseline.
Study NCT05925101 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Magnitude-drop condition
Description: In this condition, we will place destructive behavior on extinction and deliver the functional reinforcer contingent on the FCR according to a VI 1.5-s schedule, but we will deliver the reinforcer for just 6 s each time. This change from delivering 60 s of access to the functional reinforcer following destructive behavior in baseline to delivering 6 s of reinforcer access for the FCR during FCT will produce a large reduction in the magnitude of reinforcement relative to baseline.
Study NCT05925101 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Magnitude-hold condition
Description: This condition will be identical to the magnitude-drop condition except that we will deliver 60 s of access to the functional reinforcer contingent on the FCR, so that the magnitude of reinforcement will equal that delivered in baseline for destructive behavior. To ensure that the magnitude of reinforcement does not drop in the magnitude-hold condition, we will yoke the rate and timing of reinforcer deliveries for the FCR during FCT to the rate and timing of reinforcer deliveries for destructive behavior in baseline.
Study NCT05284149 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hirsutella Sinensis Nutrient Supplements
Description: This randomized control study will be conducted in 2 years. We expect to recruit 50 participants with age ≥ 50 years old. Enrolled participants will be recruited into Hirsutella Sinensis nutrient supplement group (50 patients H.S. suppl.) . The medication will be given to the participants by a third party.~All participants will have two different follow-up periods (6, 12 months). These follow-ups included clinical, laboratory, and imaging studies to analyze muscle health changes after receiving Hirsutella Sinensis nutrient supplement.
Study NCT05284149 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: We expect to recruit 50 placebo participants with age ≥ 50 years old. This randomized control study will be conducted in 2 years. The placebo will be given to the participants by a third party.~All participants will have two different follow-up periods (6, 12 months). These follow-ups included clinical, laboratory, and imaging studies to analyze muscle health changes after receiving placebo.
Study NCT05925101 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality-drop condition
Description: In this condition, we will place destructive behavior on extinction and deliver the reinforcer from the paired-choice assessment that the participant chooses approximately 1/12th as often as the highest preference stimulus from that assessment. This change from the most preferred stimulus from the paired-choice assessment to one chosen 1/12th as often will constitute a large drop in the quality of reinforcement during FCT relative to baseline.
Study NCT05925101 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quality-hold condition
Description: We will place destructive behavior on extinction and deliver the most preferred reinforcer from the paired-choice assessment on a yoked VI 1.5-s schedule that exactly matches the rate and timing of reinforcer deliveries for destructive behavior in baseline in this condition.
Study NCT05925101 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rate-drop/quality-increase condition
Description: In this condition, we will program the same large drop in reinforcement by delivering reinforcement on a VI 15-s schedule, but we also will increase reinforcement quality by simultaneously delivering the highest quality reinforcer identified during a competing stimulus assessment. We will use the competing stimulus assessment in Ex 4 because it directly assesses the quality of alternative reinforcement relative to the quality of the reinforcer for destructive behavior, whereas the paired-choice assessment could not guarantee that the selected stimulus would be of a higher quality than the reinforcer for destructive behavior.
Study NCT05911230 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Advanced diffusion-weighted MRI (ADW-MRI)
Description: An advanced diffusion weighted MRI-sequence will be performed in addition to the routine MRI-diagnostics. This will require the patient to be scanned for additional 30 minutes in a separate MRI-scanner. This technique offers the opportunity of higher sensitivity towards subtle tissue changes associated with increased specificity relating to damage of different tissue components of the CNS. In the case of surgical resection, the histopathological findings will be correlated to the findings of the ADW-MRI.
Study NCT04386980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resiniferatoxin
Description: Resiniferatoxin is a compound purified from natural sources.
Study NCT04386980 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Diluent in normal saline
Study NCT05532839 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval training
Description: The therapy lasted 6 weeks, and HIIT comprised of two 12-24 × 30 second high-intensity runs separated by thirty seconds of relaxation.
Study NCT05532839 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate intensity continuous training
Description: The MICT ran continuously for 24-48 minutes. From the day of the six weeks intervention strategies, the mentioned assays were conducted: Yo-Yo Intermittent Recovery Test level 1, repeated sprint ability , sprint test, alter of way test which is t drill, and physical activity enjoyment scale and shuttle run. Through these trainings, individuals in both groups must follow the old their balanced meal.
Study NCT05673512 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Injection of IAH0968 + CAPEOX
Description: PLACEBO+CAPEOX in HER2 positive metastatic colorectal cancer patient
Study NCT05673512 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: PLACEBO+CAPEOX
Description: PLACEBO+CAPEOX in HER2 positive metastatic colorectal cancer patient
Study NCT05330182 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LMN-201
Description: LMN-201 consists of orally delivered whole, dried, non-viable biomass of spirulina (Arthrospira platensis) grown from 4 separate strains, each of which has been engineered to express one of the following therapeutic proteins:~* 3 toxin-binding proteins that bind and inhibit C. difficile toxin B (TcdB), an essential virulence factor for C. difficile~* 1 lysozyme-like enzyme that selectively degrades the cell wall of C. difficile and causes rapid destruction of the organism
Study NCT05330182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LMN-201
Description: LMN-201 consists of orally delivered whole, dried, non-viable biomass of spirulina (Arthrospira platensis) grown from 4 separate strains, each of which has been engineered to express one of the following therapeutic proteins:~* 3 toxin-binding proteins that bind and inhibit C. difficile toxin B (TcdB), an essential virulence factor for C. difficile~* 1 lysozyme-like enzyme that selectively degrades the cell wall of C. difficile and causes rapid destruction of the organism
Study NCT05330182 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Doses of placebo will be delivered as identical-appearing cornstarch with coloring in size 00, white, opaque, capsules.
Study NCT05445843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JDQ443
Description: JDQ443 orally administered
Study NCT06118034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 MG
Description: Take 0.5mg of colchicine tablets orally for 3 days before surgery, and continued to take 0.5mg every other day (qod) for 10 days after tracheal extubation.
Study NCT06118034 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take 0.5mg of starch tablets orally for 3 days before surgery, and continued to take 0.5mg every other day (qod) for 10 days after tracheal extubation.
Study NCT05010031 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative radiotherapy
Description: An initial cohort of 12 evaluable patients will be treated with 4Gyx2, with adaptive dosing planned for expansion cohorts pending the number of failures observed after 6 month observation of the initial cohort.
Study NCT05471037 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Long Biliopancreatic Limb LRYGB
Description: LRYGB with an 180 cm biliopancreatic limb (BPL) and an alimentary limb (AL) of 80 cm.
Study NCT05471037 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Short Biliopancreatic Limb LRYGB
Description: Standard LRYGB with a 80 cm BPL and a 180 cm long AL.
Study NCT06393517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06954522 MR (Formulation 2)
Description: Participants to receive a single dose (Dose Level 1 and 2) of PF-06954522 Formulation 2 by mouth.
Study NCT04328584 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical navigation system
Description: Navigation system providing surgeons with an additional view of the chest wall lesion